Faculty

Back to Index
David Geller, MD, PhD
Professor of Clinical Pediatrics
Pediatrics
CHLA 4650 W. Sunset Blvd. Off Campus Los Angeles

Publications

. View in: PubMed

. View in: PubMed

Inhalation of tobramycin using simulated cystic fibrosis patient profiles. Pediatr Pulmonol. 2016 Nov; 51(11):1159-1167. View in: PubMed

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 Jul; 15(4):495-502. View in: PubMed

Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. J Cyst Fibros. 2015 Sep; 14(5):608-14. View in: PubMed

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14. View in: PubMed

Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulm Pharmacol Ther. 2014 Dec; 29(2):217-23. View in: PubMed

Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014 Jul; 49(7):650-8. View in: PubMed

Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respir Care. 2014 Mar; 59(3):388-98. View in: PubMed

Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195. View in: PubMed

Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76. View in: PubMed

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724. View in: PubMed

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-24. View in: PubMed

Improvements in quality of life after surgery for benign hepatic tumors: Results from a dual center analysis. Surgery. 2012 Aug; 152(2):193-201. View in: PubMed

Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52. View in: PubMed

A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol. 2012 Mar; 47(3):252-63. View in: PubMed

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2012 Jan 15; 185(2):171-8. View in: PubMed

Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? J Surg Oncol. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases? J Surg Oncol. 2012 Jan; 105(1):55-9. View in: PubMed

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respir Med. 2011 Dec; 105 Suppl 2:S2-8. View in: PubMed

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6. View in: PubMed

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40. View in: PubMed

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 1; 183(11):1510-6. View in: PubMed

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol. 2011 Mar; 46(3):230-8. View in: PubMed

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61. View in: PubMed

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review. Med Devices (Auckl). 2011; 4:179-88. View in: PubMed

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007 Apr; 42(4):307-13. View in: PubMed

A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006 Aug; 5(3):177-85. View in: PubMed

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest. 2003 Jan; 123(1):28-36. View in: PubMed

Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. J Aerosol Med. 2003; 16(2):175-82. View in: PubMed

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002 Jul; 122(1):219-26. View in: PubMed

Powered bySC CTSI